{
"id":"mk19_b_cv_s13",
"subspecialtyId":"cv",
"title":"Pregnancy and Cardiovascular Disease",
"jsonContent":{
"type":"section",
"id":"mk19_b_cv_s13",
"title":{
"__html":"Pregnancy and Cardiovascular Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"1aa0b4",
"children":[
"Pregnancy and Cardiovascular Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_cv_s13_0",
"children":[
{
"type":"p",
"hlId":"9a859c",
"children":[
"Maternal mortality has increased in the United States while decreasing in other Western countries over the past two decades. Acquired cardiovascular disorders (cardiomyopathy, coronary artery disease, aortic disorders) are the most common cause of maternal mortality."
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_1",
"title":{
"__html":"Cardiovascular Changes During Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"9befe9",
"children":[
"Cardiovascular Changes During Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"a9e5ba",
"children":[
"Knowledge of the cardiovascular changes of pregnancy is necessary to distinguish between normal and pathologic signs and symptoms in the pregnant patient ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_cv_t45",
"wrapId":"1",
"children":[
"Table 45"
]
}
]
},
")"
]
},
". During a normal pregnancy, patients develop a relative anemia due to increases in plasma volume and, to a lesser degree, erythrocyte mass. Mean arterial pressure slightly decreases in the setting of reduced systemic vascular resistance and increased heart rate and cardiac output. By the 32nd week of pregnancy, maternal cardiac output peaks at approximately 40% to 50% above the prepregnancy level owing to increased heart rate and stroke volume. During delivery, the cardiac output may increase to as much as 80% above the prepregnancy level."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_cv_t45"
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_2",
"title":{
"__html":"Prepregnancy Evaluation"
},
"titleNode":{
"type":"section-title",
"hlId":"8cef31",
"children":[
"Prepregnancy Evaluation"
]
},
"children":[
{
"type":"p",
"hlId":"987488",
"children":[
"All women with cardiovascular disease should receive pregnancy counseling. If appropriate, women should receive genetic counseling and possibly testing. Women who are anticipating pregnancy should undergo multidisciplinary evaluation with a cardiologist, a maternal-fetal medicine specialist, and an obstetric anesthesiologist to determine the risks of pregnancy and develop a management plan for labor and the postpartum period. Disease-specific risk should be assessed using the modified World Health Organization pregnancy risk classification (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://academic.oup.com/view-large/186437995",
"target":"_blank"
},
"children":[
"https://academic.oup.com/view-large/186437995"
]
},
"), which is currently the most accurate system of risk assessment."
]
},
{
"type":"p",
"hlId":"4c7273",
"children":[
"Women with certain cardiovascular disorders, including uncomplicated small patent ductus arteriosus, mild pulmonary stenosis, and mitral valve prolapse, have no increased morbidity or mortality. Similarly, pregnant patients with successfully repaired simple lesions (atrial or ventricular septal defect, patent ductus arteriosus, or anomalous pulmonary venous drainage) or isolated atrial or ventricular ectopic beats do well. These patients can be cared for and deliver in a local hospital."
]
},
{
"type":"p",
"hlId":"bb6fbc",
"children":[
"Small increased risk of maternal mortality or moderate increase in morbidity is associated with an unrepaired atrial or ventricular septal defect, repaired tetralogy of Fallot, most arrhythmias (supraventricular arrhythmias), and Turner syndrome without aortic dilatation. Patients with these conditions also can be cared for and deliver in a local hospital setting."
]
},
{
"type":"p",
"hlId":"d11398",
"children":[
"Cardiovascular conditions that confer an extremely high risk for maternal mortality or severe morbidity include pulmonary hypertension, previous peripartum cardiomyopathy with residual left ventricular dysfunction, severe left ventricular dysfunction (ejection fraction <30% or New York Heart Association functional class III-IV symptoms), severe mitral stenosis, symptomatic severe aortic stenosis, and marked ascending aorta dilatation. Care and delivery should be performed at an expert center for pregnancy and cardiac disease."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e5003c",
"children":[
"Women with cardiovascular disease who are anticipating pregnancy should undergo multidisciplinary prepregnancy evaluation."
]
},
{
"type":"keypoint",
"hlId":"de5cb2",
"children":[
"Cardiovascular conditions that confer an extremely high risk for maternal mortality or severe morbidity include pulmonary hypertension, previous peripartum cardiomyopathy with residual left ventricular dysfunction, severe left ventricular dysfunction (ejection fraction <30% or New York Heart Association functional class III-IV symptoms), severe mitral stenosis, symptomatic severe aortic stenosis, and marked ascending aorta dilatation."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_3",
"title":{
"__html":"Management of Cardiovascular Disease During Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"1f9f42",
"children":[
"Management of Cardiovascular Disease During Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"f1f32a",
"children":[
"Women with obstructive valvular lesions may experience symptoms during pregnancy because of the resultant increases in blood volume and cardiac output. These patients should be evaluated to determine whether cardiac intervention should be considered before pregnancy. Women with regurgitant valve lesions usually tolerate pregnancy well. Women with symptomatic obstructive hypertrophic cardiomyopathy should be treated with nonvasodilating β-blockers, with monitoring of fetal growth."
]
},
{
"type":"p",
"hlId":"1f19d6",
"children":[
"Vaginal delivery is generally preferred for patients with cardiovascular disease because it results in less blood loss, quicker recovery, and lower risk for thrombosis than does cesarean delivery. Cesarean delivery is recommended for obstetric reasons in women with severe decompensated cardiovascular disease and in some patients with a markedly dilated aorta. In women receiving warfarin therapy, cesarean delivery is indicated to reduce the risk for fetal intracranial hemorrhage because the fetus is fully anticoagulated."
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_3_1",
"title":{
"__html":"Peripartum Cardiomyopathy"
},
"titleNode":{
"type":"section-title",
"hlId":"8f5d6d",
"children":[
"Peripartum Cardiomyopathy"
]
},
"children":[
{
"type":"p",
"hlId":"a39eb4",
"children":[
"Peripartum cardiomyopathy is left ventricular systolic dysfunction recognized toward the end of pregnancy or in the months following delivery in the absence of another identifiable cause. Risk factors for peripartum cardiomyopathy include multiparity, age older than 30 years, multifetal pregnancy, gestational hypertension, preeclampsia, a previous episode of peripartum cardiomyopathy, and tocolytic therapy (e.g., terbutaline). Patients with peripartum cardiomyopathy should be co-managed by a cardiologist."
]
},
{
"type":"p",
"hlId":"0dcb89",
"children":[
"Death in women with peripartum cardiomyopathy is caused by heart failure, thromboembolic events, or arrhythmias. Most women who develop peripartum cardiomyopathy recover fully, as measured by improvement in ejection fraction; however, in a prospective study, 13% had major cardiovascular events or persistent severe cardiomyopathy. Studies suggest that the time frame for recovery is 6 months. Prognostic factors that portend a worse outcome include severe left ventricular dysfunction/dilatation at presentation, older maternal age, and multiparity."
]
},
{
"type":"p",
"hlId":"d6c5a7",
"children":[
"Women with peripartum cardiomyopathy should be promptly treated with medical therapy that may include β-blockers, digoxin, hydralazine, nitrates, and diuretics. ACE inhibitors, angiotensin receptor blockers, and aldosterone antagonists are teratogenic and should be avoided until after delivery. Owing to the high risk for thromboembolism associated with peripartum cardiomyopathy, anticoagulation is recommended for women with left ventricular ejection fraction below 35%. The choice of anticoagulant (heparin or warfarin) depends on whether the patient is still pregnant and the time since delivery. Duration of anticoagulation is at least 8 weeks, although therapy can be discontinued sooner if the ejection fraction normalizes."
]
},
{
"type":"p",
"hlId":"cda012",
"children":[
"Women with severe refractory heart failure due to peripartum cardiomyopathy should be referred to a specialty center for advanced treatment, including ventricular assist device placement, advanced arrhythmia management, and heart transplantation."
]
},
{
"type":"p",
"hlId":"a15137",
"children":[
"Because subsequent pregnancy is often associated with recurrent or further reduction of left ventricular function, potentially resulting in clinical deterioration or death, women with a previous episode of peripartum cardiomyopathy with persistent left ventricular dysfunction should be advised to avoid future pregnancy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_3_2",
"title":{
"__html":"Other Cardiovascular Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"558a6a",
"children":[
"Other Cardiovascular Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"97db22",
"children":[
"Data have linked adverse pregnancy outcomes (hypertensive disorders of pregnancy, preterm delivery, glucose intolerance during pregnancy, small-for-gestational-age delivery, placental abruption, and pregnancy loss) with the acquisition of cardiovascular risk factors and cardiovascular disease. It is unknown how this information should be used to reclassify cardiovascular risk in affected women, but a heart-healthy diet and exercise are recommended beginning in the postpartum period and extending throughout the lifespan."
]
},
{
"type":"p",
"hlId":"00d6ee",
"children":[
"Women with Marfan syndrome and related conditions have an increased risk for pregnancy-related aortic dissection. Aortic repair is recommended before pregnancy in women with Marfan syndrome and an aortic diameter of 4.5 cm or greater. Risk factors for dissection in pregnant patients with Marfan syndrome and an aortic diameter smaller than 4.5 cm include rapid dilatation of the aorta or a personal or family history of aortic dissection. Patients with risk factors and an ascending aortic diameter greater than 4.0 cm should be counseled to undergo aortic valve repair or replacement before pregnancy."
]
},
{
"type":"p",
"hlId":"5cb860",
"children":[
"Spontaneous coronary artery dissection is the leading cause of pregnancy-associated myocardial infarction and occurs most commonly in the first month postpartum (see ",
{
"type":"cross-reference",
"target":"mk19_b_cv_s3_2_5",
"children":[
"Coronary Artery Disease"
]
},
"). Conservative noninterventional therapy is preferred for most patients."
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_3_3",
"title":{
"__html":"Cardiovascular Medication Use During Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"c0a724",
"children":[
"Cardiovascular Medication Use During Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"74ee90",
"children":[
"Guidelines for the use of select cardiovascular drugs during pregnancy are outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_cv_t46",
"wrapId":"2",
"children":[
"Table 46"
]
}
]
},
". Most cardiovascular drugs are not FDA-approved for use during pregnancy because of limited safety data. Cardiovascular medications should be used only when needed and at the lowest possible dosage, with the desired therapeutic effect outweighing the risk."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_cv_t46"
]
},
{
"type":"p",
"hlId":"2deecd",
"children":[
"β-Blocker use during pregnancy or lactation requires periodic fetal and newborn heart rate monitoring because β-blockers cross the placenta and are present in human breast milk. Labetalol is the preferred β-blocker in this setting. Atenolol has been linked to premature delivery and small-for-gestational-age babies and thus is usually avoided during pregnancy."
]
},
{
"type":"p",
"hlId":"670e0d",
"children":[
"Adenosine is the drug of choice for treatment of acute symptomatic supraventricular tachycardia during pregnancy. Recurrent episodes of tachycardia are often treated with β-blockers; sotalol and flecainide have also been used safely. Because of toxicity concerns, amiodarone is used rarely."
]
},
{
"type":"p",
"hlId":"ab3d6b",
"children":[
"ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, and aldosterone antagonists should be avoided during pregnancy, although some ACE inhibitors and spironolactone are safe to use while breastfeeding. There is inconclusive evidence on the safety of direct renin inhibitors and angiotensin receptor blockers while breastfeeding; these drugs are generally avoided during lactation."
]
},
{
"type":"p",
"hlId":"766199",
"children":[
"A useful source of information on drugs to which breastfeeding mothers may be exposed, including potential adverse effects and suggested therapeutic alternatives, is the LactMed database (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm",
"target":"_blank"
},
"children":[
"https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_3_4",
"title":{
"__html":"Anticoagulation Therapy During Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"bf6186",
"children":[
"Anticoagulation Therapy During Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"a68cf8",
"children":[
"Pregnancy is associated with hypercoagulability. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_cv_t47",
"wrapId":"3",
"children":[
"Table 47"
]
}
]
},
" lists the indications for anticoagulation in pregnancy, recommended regimens, and monitoring parameters for therapy. Prepregnancy counseling is recommended for all women requiring long-term anticoagulation to enable them to make informed decisions regarding anticoagulant preference and to understand the maternal and fetal risks."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_cv_t47"
]
},
{
"type":"p",
"hlId":"8119ad",
"children":[
"Warfarin, unfractionated heparin, and low-molecular-weight heparin can all be used during pregnancy. Careful monitoring and dosage adjustment to attain the therapeutic target are indicated for all anticoagulation regimens. Warfarin use during the first trimester can cause warfarin embryopathy; the risk is increased when the daily dose is greater than 5 mg. Warfarin is stopped before delivery owing to the risk for fetal intracranial hemorrhage if spontaneous labor and vaginal delivery occur while the mother (and thus the fetus) is anticoagulated with warfarin."
]
},
{
"type":"p",
"hlId":"7a90f4",
"children":[
"Pregnant women with a mechanical valve prosthesis represent a high-risk subset of patients. Concerns include valve thrombosis with its associated maternal risks, bleeding, and fetal morbidity and mortality. Warfarin appears to be the safest agent to prevent maternal prosthetic valve thrombosis; however, warfarin poses an increased fetal risk, with possible teratogenicity, miscarriage, and fetal loss. Data suggest that low-molecular-weight heparin and unfractionated heparin are safer for the fetus than warfarin, but these therapies appear to increase the risk for maternal prosthetic valve thrombosis."
]
},
{
"type":"p",
"hlId":"3e00ea",
"children":[
"Guidelines from the American College of Cardiology/American Heart Association on the management of anticoagulation during pregnancy in the setting of mechanical valve prosthesis recommend warfarin during the first trimester if the daily dose is 5 mg or less at the time of conception. Intravenous unfractionated heparin or dose-adjusted low-molecular-weight heparin is preferred if the warfarin dose is more than 5 mg daily. During the second and early third trimesters, warfarin therapy is preferred. Intravenous unfractionated heparin is preferred for anticoagulation around the time of delivery in patients with a mechanical valve prosthesis. At least weekly monitoring of the anticoagulation level is recommended during pregnancy regardless of the regimen used, with dosage adjustment as indicated."
]
},
{
"type":"p",
"hlId":"66bdb9",
"children":[
"In patients receiving direct oral anticoagulants, it is recommended that pregnancy and lactation be avoided because of limited data related to safety. If a woman becomes pregnant while taking a direct oral anticoagulant, therapy should be switched to an appropriate alternative anticoagulant (heparin or warfarin)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8e4439",
"children":[
"Women with peripartum cardiomyopathy who present before delivery should be treated with medical therapy that may include β-blockers, digoxin, hydralazine, nitrates, or diuretics; ACE inhibitors, angiotensin receptor blockers, and aldosterone antagonists can be used in patients presenting postpartum but should be avoided during pregnancy because of teratogenicity."
]
},
{
"type":"keypoint",
"hlId":"c04456",
"children":[
"In pregnant patients with a mechanical valve prosthesis, warfarin anticoagulation is preferred during the first trimester if the daily dose is 5 mg or less; intravenous unfractionated heparin or dose-adjusted low-molecular-weight heparin is preferred if the warfarin dose is more than 5 mg daily."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_cv_s13_4",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016;133:1397-409. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27045128",
"target":"_blank"
},
"children":[
"PMID: 27045128"
]
},
" doi:10.1161/CIRCULATIONAHA.115.020491"
]
},
{
"type":"reference",
"children":[
"McNamara DM, Elkayam U, Alharethi R, et al; IPAC Investigators. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015;66:905-14. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26293760",
"target":"_blank"
},
"children":[
"PMID: 26293760"
]
},
" doi:10.1016/j.jacc.2015.06.1309"
]
},
{
"type":"reference",
"children":[
"Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72-e227. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33332150",
"target":"_blank"
},
"children":[
"PMID: 33332150"
]
},
" doi:10.1161/CIR.0000000000000923"
]
},
{
"type":"reference",
"children":[
"Parikh NI, Gonzalez JM, Anderson CAM, et al; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and the Stroke Council. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation. 2021;143:e902-e916. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33779213",
"target":"_blank"
},
"children":[
"PMID: 33779213"
]
},
" doi:10.1161/CIR.0000000000000961"
]
},
{
"type":"reference",
"children":[
"Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39:3165-3241. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30165544",
"target":"_blank"
},
"children":[
"PMID: 30165544"
]
},
" doi:10.1093/eurheartj/ehy340"
]
},
{
"type":"reference",
"children":[
"Tweet MS, Hayes SN, Codsi E, et al. Spontaneous coronary artery dissection associated with pregnancy. J Am Coll Cardiol. 2017;70:426-435. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28728686",
"target":"_blank"
},
"children":[
"PMID: 28728686"
]
},
" doi:10.1016/j.jacc.2017.05.055"
]
},
{
"type":"reference",
"children":[
"van Hagen IM, Roos-Hesselink JW, Ruys TP, et al; ROPAC Investigators and the EURObservational Research Programme (EORP) Team*. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 2015;132:132-42. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26100109",
"target":"_blank"
},
"children":[
"PMID: 26100109"
]
},
" doi:10.1161/CIRCULATIONAHA.115.015242"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_cv_t45":{
"id":"mk19_b_cv_t45",
"number":45,
"bookId":"cv",
"title":{
"__html":"Normal Versus Pathologic Signs and Symptoms in Pregnancy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"afd157",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 45. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_cv_t45"
}
]
},
"Normal Versus Pathologic Signs and Symptoms in Pregnancy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da0a8d",
"class":"col hd l",
"children":[
"Type of Sign or Symptom"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"960b44",
"class":"col hd l",
"children":[
"Normal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2a80a",
"class":"col hd l",
"children":[
"Pathologic"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a36efb",
"class":"cell txt l",
"children":[
"Pulmonary"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"28be5a",
"class":"cell txt l",
"children":[
"Mild dyspnea, dyspnea with exertion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7207a0",
"class":"cell txt l",
"children":[
"Orthopnea, paroxysmal nocturnal dyspnea, cough, pulmonary edema"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d521f",
"class":"cell txt l",
"children":[
"Cardiac"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"370436",
"class":"cell txt l",
"children":[
"No symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"219eea",
"class":"cell txt l",
"children":[
"Chest pressure, heaviness, or pain"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae7cf2",
"class":"cell txt l",
"children":[
"Edema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f64a8",
"class":"cell txt l",
"children":[
"Mild peripheral edema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7675d0",
"class":"cell txt l",
"children":[
"More than mild edema"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bc652",
"class":"cell txt l",
"children":[
"Heart rhythm"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"28949e",
"class":"cell txt l",
"children":[
"Atrial and ventricular premature beats"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2c8d5",
"class":"cell txt l",
"children":[
"Atrial fibrillation or flutter, ventricular tachycardia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d287b",
"class":"cell txt l",
"children":[
"Heart rate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f05ad",
"class":"cell txt l",
"children":[
"Heart rate increased by 20%-30%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2805c",
"class":"cell txt l",
"children":[
"Heart rate >100/min"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"398b09",
"class":"cell txt l",
"children":[
"Blood pressure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b3a399",
"class":"cell txt l",
"children":[
"Blood pressure typically is modestly decreased (~10 mm Hg)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"848dc8",
"class":"cell txt l",
"children":[
"Low blood pressure associated with symptoms, high blood pressure (≥140 mm Hg systolic or ≥90 mm Hg diastolic)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e7599",
"class":"cell txt l",
"children":[
"Auscultatory"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bc462",
"class":"cell txt l",
"children":[
"Basal systolic murmur grade 1/6 or 2/6 present in 80% of pregnant women, S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"3"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"783ada",
"class":"cell txt l",
"children":[
"Systolic murmur grade ≥3/6, any diastolic murmur, S",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"4"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_cv_t46":{
"id":"mk19_b_cv_t46",
"number":46,
"bookId":"cv",
"title":{
"__html":"Safety of Drugs for Cardiac Disorders in Pregnancy and Lactation"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1f1192",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 46. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_cv_t46"
}
]
},
"Safety of Drugs for Cardiac Disorders in Pregnancy and Lactation"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"acdf6f",
"class":"col hd l",
"children":[
"Use in Pregnancy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c468c8",
"class":"col hd l",
"children":[
"Compatibility with Breastfeeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10b7d4",
"class":"cell txt l",
"children":[
"ACE inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"22be5c",
"class":"cell txt li",
"children":[
"Captopril, enalapril"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"047894",
"class":"cell txt l",
"children":[
"Teratogenic in first trimester; cause fetal/neonatal kidney failure with second- or third-trimester exposure; scleroderma renal crisis is only indication"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef7578",
"class":"cell txt li",
"children":[
"Lisinopril"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"95b197",
"class":"cell txt l",
"children":[
"Same as above"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29890d",
"class":"cell txt l",
"children":[
"Aliskiren"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ad77c",
"class":"cell txt l",
"children":[
"Teratogenic in first trimester; causes fetal/neonatal kidney failure with second- or third-trimester exposure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"156b28",
"class":"cell txt l",
"children":[
"ARBs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3a125",
"class":"cell txt l",
"children":[
"Teratogenic in first trimester; cause fetal/neonatal kidney failure with second- or third-trimester exposure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0bbe87",
"class":"cell txt l",
"children":[
"Adenosine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca1bea",
"class":"cell txt l",
"children":[
"No change in fetal heart rate when used for supraventricular tachycardia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fccce3",
"class":"cell txt l",
"children":[
"Amiodarone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2e674",
"class":"cell txt l",
"children":[
"Fetal hypothyroidism, prematurity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a839c",
"class":"cell txt l",
"children":[
"Antiplatelet and anticoagulant agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"92ba45",
"class":"cell txt li",
"children":[
"Dipyridamole, clopidogrel"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ec599",
"class":"cell txt l",
"children":[
"Second-line agent; no evidence of harm in animal clopidogrel studies; no human data"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"afdb64",
"class":"cell txt li",
"children":[
"Aspirin (≤81 mg)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eab4a4",
"class":"cell txt li",
"children":[
"DOACs (apixaban, dabigatran, rivaroxaban, edoxaban, betrixaban)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"db6115",
"class":"cell txt l",
"children":[
"Pregnancy and lactation should be avoided in DOAC-treated patients; available data do not suggest a high risk for DOAC embryopathy or neonatal complications"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89aad3",
"class":"cell txt l",
"children":[
"β-Blockers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"842e4a",
"class":"cell txt li",
"children":[
"Atenolol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5d930",
"class":"cell txt l",
"children":[
"Second-line agent; low birth weight, intrauterine growth restriction"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"836a00",
"class":"cell txt li",
"children":[
"Esmolol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a27281",
"class":"cell txt l",
"children":[
"Second-line agent; more pronounced bradycardia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ce2ec",
"class":"cell txt li",
"children":[
"Labetalol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ff345",
"class":"cell txt l",
"children":[
"Preferred drug in class"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"85931b",
"class":"cell txt li",
"children":[
"Metoprolol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aa014a",
"class":"cell txt l",
"children":[
"Shortened half-life"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26d2fb",
"class":"cell txt li",
"children":[
"Propranolol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"585d3b",
"class":"cell txt l",
"children":[
"Second-line agent; intrauterine growth restriction"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47f629",
"class":"cell txt li",
"children":[
"Sotalol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30e3a8",
"class":"cell txt l",
"children":[
"Second-line agent; insufficient data; reserve use for arrhythmia not responding to alternative agent"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3596ea",
"class":"cell txt l",
"children":[
"Calcium channel blockers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a08d5",
"class":"cell txt li",
"children":[
"Diltiazem, verapamil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"689cf4",
"class":"cell txt l",
"children":[
"Second-line agent; maternal hypotension with rapid intravenous infusion; used for fetal supraventricular tachycardia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2e248",
"class":"cell txt l",
"children":[
"Digoxin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de0d86",
"class":"cell txt l",
"children":[
"Second-line agent; shortened half-life"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c64c66",
"class":"cell txt l",
"children":[
"Disopyramide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"264584",
"class":"cell txt l",
"children":[
"Second-line agent; case reports of preterm labor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"808737",
"class":"cell txt l",
"children":[
"Diuretics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7baab0",
"class":"cell txt l",
"children":[
"Second-line agent; use when needed for maternal volume overload only"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"536354",
"class":"cell txt l",
"children":[
"Flecainide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed674",
"class":"cell txt l",
"children":[
"Second-line agent; inadequate data but used for fetal arrhythmia; case report of fetal hyperbilirubinemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-13 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39fcde",
"class":"cell txt l",
"children":[
"Hydralazine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1700f",
"class":"cell txt l",
"children":[
"Vasodilator of choice"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-14 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"178354",
"class":"cell txt l",
"children":[
"Lidocaine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fe86f",
"class":"cell txt l",
"children":[
"Treatment of choice for ventricular arrhythmias"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-15 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e54ea",
"class":"cell txt l",
"children":[
"Sodium nitroprusside"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec3475",
"class":"cell txt l",
"children":[
"Potential fetal thiocyanate toxicity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-16 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b4fda0",
"class":"cell txt l",
"children":[
"Organic nitrates"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cc0ba",
"class":"cell txt l",
"children":[
"No apparent increased risk"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-17 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"221fb3",
"class":"cell txt l",
"children":[
"Phenytoin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bafd73",
"class":"cell txt l",
"children":[
"No"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"473555",
"class":"cell txt l",
"children":[
"Known teratogenicity and bleeding risk; last resort for arrhythmia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-18 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e52588",
"class":"cell txt l",
"children":[
"Procainamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16e440",
"class":"cell txt l",
"children":[
"Used for fetal arrhythmia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-19 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d18b0e",
"class":"cell txt l",
"children":[
"Propafenone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1457b",
"class":"cell txt l",
"children":[
"?"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d23b9",
"class":"cell txt l",
"children":[
"Second-line agent; used for fetal arrhythmia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-20 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ecbb16",
"class":"cell txt l",
"children":[
"Quinidine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93cba0",
"class":"cell txt l",
"children":[
"Yes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1f710",
"class":"cell txt l",
"children":[
"Preferred drug in class; increases digoxin levels"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"? = unknown; ARB = angiotensin receptor blocker; DOAC = direct oral anticoagulant."
],
[
"Adapted with permission from Rosene-Montella K, Keely EJ, Lee RV, et al. Medical care of the pregnant patient. 2nd edition. Philadelphia, PA: American College of Physicians; 2008. pp 356-357. ©2008 American College of Physicians."
]
]
},
"mk19_b_cv_t47":{
"id":"mk19_b_cv_t47",
"number":47,
"bookId":"cv",
"title":{
"__html":"Anticoagulation Regimens During Pregnancy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"0b1f70",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 47. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_cv_t47"
}
]
},
"Anticoagulation Regimens During Pregnancy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b07cd",
"class":"col hd l",
"children":[
"Weeks of Gestation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"390eeb",
"class":"col hd l",
"children":[
"Recommended Regimen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"934476",
"class":"col hd l",
"children":[
"Venous Thromboembolism"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dac39a",
"class":"cell txt l",
"children":[
"Weeks 6 to term"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d28627",
"class":"cell txt l",
"children":[
"Weight-based LMWH"
]
},
" ",
{
"type":"p",
"hlId":"22991e",
"class":"cell txt l",
"children":[
"UFH (IV or SQ; aPTT 2 × control)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"3d0b99",
"class":"col hd l",
"children":[
"Nonvalvular Atrial Fibrillation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"786fe4",
"class":"cell txt l",
"children":[
"Weeks 6-12"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d1c45",
"class":"cell txt l",
"children":[
"Warfarin (if dose to attain therapeutic INR ≤5 mg)"
]
},
" ",
{
"type":"p",
"hlId":"22991e",
"class":"cell txt l",
"children":[
"UFH (IV or SQ; aPTT 2 × control)"
]
},
" ",
{
"type":"p",
"hlId":"d28627",
"class":"cell txt l",
"children":[
"Weight-based LMWH"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ad4d8",
"class":"cell txt l",
"children":[
"Weeks 13-37"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ea3e7",
"class":"cell txt l",
"children":[
"UFH (SQ; aPTT 2 × control)"
]
},
" ",
{
"type":"p",
"hlId":"d28627",
"class":"cell txt l",
"children":[
"Weight-based LMWH"
]
},
" ",
{
"type":"p",
"hlId":"46f963",
"class":"cell txt l",
"children":[
"Warfarin (therapeutic INR)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"121d94",
"class":"cell txt l",
"children":[
"Weeks 37 to term"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"910e13",
"class":"cell txt l",
"children":[
"UFH (IV; aPTT 2 × control)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"02d510",
"class":"col hd l",
"children":[
"Mechanical Valve Prosthesis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"786fe4",
"class":"cell txt l",
"children":[
"Weeks 6-12"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53f090",
"class":"cell txt l",
"children":[
"If warfarin daily dose ≤5 mg for therapeutic INR"
]
},
" ",
{
"type":"p",
"hlId":"cf920c",
"class":"cell txt li",
"children":[
"Continue warfarin (class 2a recommendation)"
]
},
" ",
{
"type":"p",
"hlId":"71c774",
"class":"cell txt li",
"children":[
"UFH: IV; aPTT 2 × control (class 2b recommendation)"
]
},
" ",
{
"type":"p",
"hlId":"785491",
"class":"cell txt li",
"children":[
"Anti–factor Xa adjusted LMWH (class 2b recommendation)"
]
},
" ",
{
"type":"p",
"hlId":"32cbb2",
"class":"cell txt l",
"children":[
"If warfarin daily dose >5 mg for therapeutic INR"
]
},
" ",
{
"type":"p",
"hlId":"eea1c5",
"class":"cell txt li",
"children":[
"UFH: IV; aPTT 2 × control (class 2a recommendation)"
]
},
" ",
{
"type":"p",
"hlId":"8c0dcd",
"class":"cell txt li",
"children":[
"Anti–factor Xa adjusted LMWH (class 2a recommendation)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ad4d8",
"class":"cell txt l",
"children":[
"Weeks 13-37"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46f963",
"class":"cell txt l",
"children":[
"Warfarin (therapeutic INR)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"121d94",
"class":"cell txt l",
"children":[
"Weeks 37 to term"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"910e13",
"class":"cell txt l",
"children":[
"UFH (IV; aPTT 2 × control)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"aPTT = activated partial thromboplastin time; IV = intravenous; LMWH = low-molecular-weight heparin; SQ = subcutaneous; UFH = unfractionated heparin."
],
[
"Recommendations from Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72-e227. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33332150",
"target":"_blank"
},
"children":[
"PMID: 33332150"
]
},
" doi:10.1161/CIR.0000000000000923 ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317-3359. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30482767",
"target":"_blank"
},
"children":[
"PMID: 30482767"
]
},
" doi:10.1182/bloodadvances.2018024802 ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154:1121-1201. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30144419",
"target":"_blank"
},
"children":[
"PMID: 30144419"
]
},
" doi:10.1016/j.chest.2018.07.040"
]
]
}
}
}